

31 July 2009

Proposal to list a new brand of amoxicillin 125 mg per 5 ml suspension

PHARMAC is seeking feedback on a proposal to fund Sandoz Pty Limited's brand of amoxicillin granules for oral liquid 125 mg per 5 ml (Ospamox) from 1 December 2009.

In summary, this proposal would result in:

- The Ospamox brand of amoxicillin granules for oral liquid 125 mg per 5 ml would be listed in section B of the of the Pharmaceutical Schedule from 1 December 2009,
- Subsidy and delisting protection for Ospamox granules for oral liquid 125 mg per 5 ml until 1 July 2012.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Friday, 21 August 2009** to:

Greg Williams
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: greg.williams@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposal

PHARMAC and Sandoz Pty Limited have entered into a provisional agreement relating to the supply of amoxicillin granules for oral liquid 125 mg per 5 ml (Ospamox).

Ospamox would be listed, in the Infections – Agents for Systemic Use therapeutic group, in Section B of the Pharmaceutical Schedule from 1 December 2009 at the following prices and subsidies (ex-manufacturer and exclusive of GST):

| Chemical | Presentation | Brand | Pack size | Price and subsidy |
|-----------------|--|--------------|------------------|--------------------------|
| Amoxicillin | 125 mg per 5 ml granules for oral liquid | Ospamox | 100ml | \$1.55 |

Up to 200 ml would be available on a Practitioner's Supply Order.

Ospamox (125 mg per 5 ml) would have subsidy and delisting protection until 1 July 2012.

Background

PHARMAC currently funds amoxicillin granules for oral liquid 125 mg per 5 ml and 250 mg per 5 ml without restriction. Amoxicillin 125 mg per 5 ml was included in the 2008/09 Invitation to Tender. The decline of all tenders for amoxicillin 125 mg per 5 ml was notified on 31 July 2009.

This proposal would secure supply of amoxicillin granules for oral liquid 125 mg per 5 ml until at least 1 July 2012.